What Is HHV-8 ?

A Comprehensive Guide to HHV-8: Transmission, Symptoms, and Treatment

Human Herpesvirus 8 (HHV-8) is a complex and fascinating virus that has been the subject of intense medical research since its discovery. Also known in the medical community as Kaposi’s sarcoma-associated herpesvirus (KSHV), this virus is unique due to its direct link to certain types of cancers. While herpesviruses like those causing cold sores or chickenpox are widely known, HHV-8 operates differently, often remaining completely silent in a healthy host while posing a severe threat to those with compromised immune systems.

Understanding HHV-8 is crucial for public health, particularly in regions where the virus is endemic and among populations vulnerable to immune suppression. This comprehensive guide will explore what HHV-8 is, how it spreads from person to person, the mechanisms it uses to infect the body, the resulting symptoms, mortality risks, and the current landscape of vaccines and antiviral treatments.

What is the Human Herpesvirus 8 (HHV-8)?

Human Herpesvirus 8 belongs to the Gammaherpesvirinae subfamily. It is a large, double-stranded DNA virus. It was first identified in 1994 by researchers Yuan Chang and Patrick S. Moore, who found fragments of the virus’s DNA in the tissue of a Kaposi’s sarcoma lesion from a patient with AIDS. This discovery was groundbreaking, as it finally identified the viral culprit behind a cancer that had become an epidemiological hallmark of the HIV/AIDS crisis.

Like all herpesviruses, HHV-8 has a biphasic life cycle consisting of a latent (dormant) phase and a lytic (active replication) phase. In the latent phase, the virus inserts its genetic material into the host cell’s nucleus and essentially hides. It expresses only a very small number of viral genes—just enough to ensure it replicates when the host cell divides, but not enough to alert the host’s immune system. During the lytic phase, the virus actively produces thousands of new viral particles, ultimately destroying the host cell to release the new viruses into the body.

The most dangerous aspect of HHV-8 is its status as an oncovirus, meaning it has the potential to cause cancer. The few genes it expresses during its dormant latency phase are highly active in promoting abnormal cell growth and preventing programmed cell death (apoptosis). Over time, this uncontrolled cell division can lead to the formation of tumors.

How Does HHV-8 Spread? Understanding Transmission Routes

The transmission of HHV-8 is not as uniform or highly contagious as the common cold or the influenza virus. The virus relies on specific routes to move from one host to another, and the primary mode of transmission often depends heavily on the geographic region and the specific demographic population.

Salivary Transmission: Research indicates that the most common way HHV-8 spreads is through saliva. The virus replicates actively in the salivary glands and the lymphoid tissue of the oropharynx, leading to viral shedding in the saliva. In endemic regions, such as parts of Sub-Saharan Africa, transmission often occurs in early childhood. This is likely due to close non-sexual contact, such as sharing utensils, sharing food, or the practice of premastication (where a caregiver pre-chews food before feeding it to an infant). Deep kissing is also a highly effective vector for salivary transmission among adults.

Sexual Transmission: In non-endemic areas, such as North America and Western Europe, HHV-8 is predominantly transmitted through sexual contact, particularly within the men who have sex with men (MSM) community. While the virus can be found in semen and cervical secretions, the concentrations are much lower than in saliva. Therefore, sexual practices that involve saliva are considered the primary drivers of transmission in these populations.

Blood Transfusions and Organ Transplantation: Because HHV-8 infects white blood cells and can reside in bodily organs, it can be transmitted iatrogenically—meaning through medical procedures. Transmission via blood transfusion is rare today in developed nations due to modern blood filtering techniques (leukoreduction), but it remains a risk in areas without such infrastructure. Organ transplantation is a more significant risk. If an organ from an HHV-8 positive donor is given to an HHV-8 negative recipient, the recipient is highly likely to contract the virus. Because transplant recipients must take immunosuppressive drugs to prevent organ rejection, they are at a very high risk of the virus rapidly causing disease.

Vertical Transmission: Transmission from a mother to her child during pregnancy or childbirth (vertical transmission) is possible but remarkably rare. Unlike other herpesviruses, such as cytomegalovirus (CMV) or herpes simplex virus (HSV), HHV-8 does not cross the placental barrier easily, making in utero infection an uncommon occurrence.

The Pathogenesis of HHV-8: How It Infects the Body

Once HHV-8 enters the body, it targets specific types of cells. Its primary targets are endothelial cells (the cells that line blood and lymphatic vessels) and B lymphocytes (a type of white blood cell crucial for immune defense). The virus attaches to the surface of these cells using specific receptors, such as integrins and heparan sulfate, and forces its way inside.

Once inside the cell, HHV-8 employs a sophisticated array of tactics to evade the immune system. The virus has evolved over millions of years to “pirate” cellular genes. It produces viral proteins that mimic human proteins, confusing the immune system. For example, it produces viral interleukin-6 (vIL-6) and a viral form of Bcl-2. These proteins prevent the infected cell from dying and promote a state of chronic inflammation, creating an environment where the virus can thrive and infected cells can multiply unchecked.

The latency phase is the primary driver of HHV-8 pathogenesis. A specific viral protein called Latency-Associated Nuclear Antigen (LANA) tethers the viral DNA to the host’s chromosomes. LANA also turns off the host cell’s tumor suppressor genes, such as p53 and retinoblastoma (Rb). By removing the “brakes” on cell division, the virus inadvertently turns the infected endothelial or B cells into cancerous cells.

Affected Systems: Where Does HHV-8 Strike?

Because HHV-8 targets endothelial cells and B lymphocytes, its effects can manifest in multiple systems throughout the body.

The Integumentary System (Skin and Mucous Membranes): This is the most visibly affected system. HHV-8 infection of endothelial cells in the skin leads to the formation of Kaposi’s sarcoma lesions. These lesions often appear first on the lower extremities, face, or inside the mouth (oral cavity).

The Lymphatic System: Since the virus targets B cells and lymphatic endothelial cells, the lymphatic system is heavily compromised. This can result in severe lymphedema (swelling of the limbs due to blocked lymph fluid) and is the primary system affected in HHV-8-related lymphatic diseases like Multicentric Castleman Disease (MCD) and Primary Effusion Lymphoma (PEL).

The Respiratory and Gastrointestinal Systems: In severe, advanced cases of Kaposi’s sarcoma, the tumors do not stay confined to the skin. They can spread to the mucosal linings of the internal organs. When the gastrointestinal tract is affected, it can cause internal bleeding and blockages. When the respiratory system (lungs) is affected, tumors can block airways and cause severe shortness of breath, a condition known as pulmonary Kaposi’s sarcoma, which is a medical emergency.

Recognizing the Symptoms of HHV-8 Infection

The manifestation of symptoms depends entirely on the status of the host’s immune system. In the vast majority of healthy individuals, primary infection with HHV-8 causes absolutely no symptoms. In some rare cases of acute primary infection, a healthy person might experience a mild, self-limiting illness characterized by a minor fever, a fleeting skin rash, and mildly swollen lymph nodes. Following this, the virus goes dormant.

However, if the host’s immune system becomes suppressed—whether due to HIV/AIDS, immunosuppressive drugs for organ transplants, or aging—the virus can awaken and cause severe diseases, each with its own distinct symptoms.

Kaposi’s Sarcoma (KS)

This is a vascular tumor that presents primarily as lesions on the skin.

• Visual Symptoms: The lesions appear as painless patches, plaques, or nodules that can be purple, red, or brown. They do not lose their color when pressed (non-blanching).
• Oral Symptoms: Lesions frequently appear on the hard palate or gums, making eating and speaking difficult.
• Internal Symptoms: If visceral KS develops, patients may experience unexplained weight loss, fever, severe gastrointestinal bleeding, coughing up blood (hemoptysis), and severe breathing difficulties.

Multicentric Castleman Disease (MCD)

This is a rare, aggressive lymphoproliferative disorder. Unlike localized KS, MCD is systemic.

• Symptoms: Patients suffer from severe, recurring fevers, drenching night sweats, fatigue, and widespread, painful enlargement of the lymph nodes (lymphadenopathy). An enlarged spleen (splenomegaly) and liver (hepatomegaly) are also common, alongside dangerous drops in red blood cell and platelet counts.

Primary Effusion Lymphoma (PEL)

This is a highly aggressive and rare type of non-Hodgkin B-cell lymphoma directly caused by HHV-8.

• Symptoms: Unlike typical lymphomas that form solid tumor masses, PEL grows as liquid in the body’s serous cavities. Patients experience massive fluid buildup around the lungs (pleural effusion), heart (pericardial effusion), or in the abdominal cavity (ascites). This leads to acute shortness of breath, chest pain, and severe abdominal swelling and discomfort.

Mortality Risk and Prognosis in HHV-8 Patients

The mortality risk associated with HHV-8 is a tale of two extremes. For individuals with an intact, healthy immune system, the mortality risk from HHV-8 is virtually zero. The virus will remain latent for the person’s entire life without causing any noticeable harm.

For the immunocompromised, however, the prognosis historically has been dire, though modern medicine has vastly improved outcomes.

Before the advent of highly active antiretroviral therapy (HAART) in the mid-1990s, epidemic (AIDS-related) Kaposi’s sarcoma was a leading cause of death among HIV-positive individuals. Visceral KS, particularly pulmonary KS, carried an exceptionally high mortality rate, with patients often succumbing to the disease within months of diagnosis.

Today, the prognosis for AIDS-related KS is generally good, provided the patient has access to and adheres to HIV medication. By suppressing HIV, the immune system recovers, CD4 T-cell counts rise, and the body regains the ability to suppress HHV-8 naturally. The KS lesions often shrink and disappear entirely without the need for chemotherapy.

In contrast, the mortality risk for Primary Effusion Lymphoma (PEL) and Multicentric Castleman Disease (MCD) remains concerningly high. PEL is notoriously resistant to standard chemotherapy, and the median survival time even with aggressive treatment is often less than a year. MCD can trigger massive inflammatory responses (cytokine storms) that lead to multi-organ failure. However, new targeted therapies are improving the survival rates for MCD patients.

Is There an HHV-8 Vaccine Available?

As of the current medical landscape, there is no FDA-approved or commercially available vaccine to prevent Human Herpesvirus 8 infection.

Developing a vaccine for HHV-8 is incredibly challenging for several reasons. First, herpesviruses are notoriously adept at hiding from the immune system. Because the virus spends the vast majority of its life cycle in a latent state inside host cells, it presents very few targets for vaccine-induced antibodies to attack. Second, the virus has a large and complex genome that codes for numerous immune-evasion proteins, essentially giving it a toolkit to dismantle the body’s immune response.

Despite these challenges, research is ongoing. Scientists are exploring various avenues, including recombinant protein vaccines targeting the viral envelope glycoproteins (the proteins the virus uses to enter cells) to prevent initial infection. Advancements in mRNA technology, which proved highly successful during the COVID-19 pandemic, have also sparked renewed interest in developing an mRNA-based vaccine for HHV-8. However, any potential vaccine is still in the preclinical or very early clinical trial phases, meaning a publicly available vaccine is likely still years, if not decades, away.

Antiviral Treatments and Management Strategies for HHV-8

A crucial medical fact to understand is that there is no cure for HHV-8. Once the virus establishes latency in a host’s cells, it cannot be eradicated. Medical treatment, therefore, focuses on two main strategies: stopping the virus from actively replicating and treating the cancers/tumors it has already caused.

Antiviral Medications

Traditional anti-herpes drugs like acyclovir, which are highly effective against cold sores, do not work well against HHV-8. This is because HHV-8 lacks the specific viral enzyme (thymidine kinase) needed to activate the drug.

Instead, doctors use intravenous antiviral medications such as ganciclovir, valganciclovir, foscarnet, and cidofovir. These drugs target the viral DNA polymerase, effectively stopping the virus from copying its DNA during the lytic phase. However, these antivirals have significant limitations:

1. They only work on actively replicating viruses (the lytic phase). Because the cancer cells in Kaposi’s sarcoma are driven by the latent phase of the virus, antivirals do not shrink existing KS tumors.
2. They carry heavy side effects, including severe kidney toxicity and bone marrow suppression.Antivirals are most successfully used as prophylaxis in organ transplant recipients to prevent the virus from activating, or in combination with other drugs to manage severe flare-ups of Multicentric Castleman Disease.

Treating the Underlying Immune Deficiency

For patients with epidemic (AIDS-related) KS, the single most effective “treatment” for the HHV-8 infection is Antiretroviral Therapy (ART) for the underlying HIV. ART stops HIV from destroying the immune system. As the immune system rebuilds, it naturally regains control over HHV-8, pushing the virus back into latency and causing tumors to regress.

Treating the Tumors (Oncological Management)

When KS tumors are large, widespread, or affecting internal organs, direct cancer treatments are required.

• Local Therapy: For a few isolated skin lesions, doctors may use cryotherapy (freezing), surgical excision, or topical retinoids.
• Chemotherapy: For aggressive or visceral KS, systemic chemotherapy is required. The standard of care is usually liposomal anthracyclines (such as pegylated liposomal doxorubicin), which deliver the drug directly to the tumor’s blood vessels while minimizing toxicity to the heart.
• Targeted Immunotherapy: For the treatment of Multicentric Castleman Disease, the monoclonal antibody Rituximab has revolutionized care. Rituximab targets a specific marker (CD20) on the surface of B-cells, destroying the B-cells that harbor the virus and dramatically reducing the dangerous inflammatory response.

Conclusion

Human Herpesvirus 8 is a masterful opportunist. To a healthy immune system, it is an invisible and harmless passenger. However, when the immune system fails, HHV-8 reveals its devastating oncogenic potential, driving the development of Kaposi’s sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman Disease. While the absence of a vaccine and a definitive virological cure presents significant clinical challenges, modern medicine has made massive strides. Through the use of targeted chemotherapies, advanced immunosuppression management, and crucially, antiretroviral therapy for HIV, diseases caused by HHV-8 have transitioned from inevitable death sentences to highly manageable conditions. Ongoing research into the virus’s molecular behavior continues to pave the way for even more targeted and effective treatments in the future.

Visit Liv Hospital.

FAQ